Our study shows that our engineered VLP efficiently delivers Cas9/gRNA RNP components into chordoma cells and tissues and achieves therapeutic levels of brachyury gene editing leading to significant inhibition of chordoma growth in vivo. This evidence concerns the gene RNPC3 and chordoma.